Healthcare out of (human) touch?

By Marta Iraola | EURACTIV.com

07-06-2023 (updated: 07-06-2023 )

Editorial/Opinion An OpinionNewsArticle is a NewsArticle that primarily expresses opinions rather than journalistic reporting of news and events.

Subscribe to EURACTIV's Health Brief, your weekly update on all things healthcare in Europe.

Print Email Facebook Twitter LinkedIn WhatsApp Telegram

While artificial intelligence (AI) in a healthcare setting can be a powerful tool, with machine learning enabling medical professionals to diagnose diseases, personalise treatments and develop new drugs, experts have urged for caution in its deployment.

Hans Danneels, CEO of Byteflies, a medical technology company that develops wearable health devices, told an event in Antwerp last week about his own experience of AI in healthcare when he had twins that needed monitoring in the hospital for nine days.

At the beginning of their stay, he explained, the twins needed nurse visits every few hours to monitor and make note of the babies’ vital signs. As the twins improved, the frequency of the visits decreased, but they stayed in the hospital.

This is where Byteflies comes into play. Danneels talked about the telemonitoring devices they develop and how they can help the patients.

"More and more, for very acute things, you will still go to the hospital, but this whole function, this monitoring will shift to the home," he said.

The idea is to simplify the monitoring work for healthcare professionals at the hospital by sending patients home with one of these devices keeping track of any changes.

He explained that the algorithm is very sensitive in order to not miss any relevant event.

"We have a human in the loop that sees and classifies the results", he explained.

The need for humans to be involved in any healthcare process dealing with AI was highlighted by Leonie de Best from Madam Therapeutics, a biotech company working to develop novel antimicrobial therapies.

She explained that it is extremely important to verify the results of data analysis made using AI because every algorithm has to be trained with data and these data sets can be biased.

De Best added that without having a curated and representative data set to analyse it is easier to misjudge the correctness of the models.

"You miss a lot, or you make really big mistakes. You put crap in you get crap out," she added.

Madam Therapeutics is using Artificial Intelligence to screen big amounts of antimicrobial peptides to create a safety profile.

Thanks to AI, her company is able to screen and analyse a hundred million randomly chosen antimicrobial peptides saving them a lot of time in the process of creating safety profiles.

"That is something that took a couple of months while otherwise, it would have taken years," she explained.

According to Carlo Boutton, AI tools cannot substitute a doctor in any case. "We should not underestimate the human brain, AI should not be a replacement but an add-on," he said.

"It is more like a stethoscope, a tool that helps doctors and nurses to really spend more time on the patient," added Byteflies’ Danneels.

There is a general agreement on the fact that in order to use these new tools in the correct way it is important to include people that understand the multidisciplinary aspect of the problem, not just the data.

Doctors are still essential in every process as they are the ones that know the background of the patient, talk to the caregivers and have a more holistic view.

Machine learning, as the examples given by the different stakeholders show, needs large datasets to analyse and reach useful results.

One of the problems companies often face is difficult access to the necessary information, especially when it comes to accessing patients’ data from hospitals or clinics.

Data sharing is a controversial topic among stakeholders, as they all recognised the need to have access to patients’ information, reactions to therapies and clinical trials, among others.

At the same time, as business companies, they are reluctant to give their clients’ data away.

Madam Therapeutics’ de Best explained the need for data to be as complete and comprehensive as possible in order to make studies truly representative.

For that, Danneels stressed the need for people to own their own data so they don't depend on big tech companies and their interests in the future.

As he told EURACTIV, he welcomes the European's Commission proposal for a European Health Data Space (EHDS) to harmonise all the data that already exists in the EU.

According to Danneels, it is the best solution also for companies so they don't need to work with 27 different frameworks and will be able to compare information between countries.

"There is a big risk, and it is not regulation itself but that is too slow," he said. "It is important to give oxygen to innovation and to companies to grow in a framework, that is aligned with how Europe looks at data."

– By Marta Iraola

Subscribe to EURACTIV's Health Brief, where you’ll find the latest roundup of news covering health from across Europe. The Health Brief is brought to you by EURACTIV's Health Team Giedrė Peseckytė, Clara Bauer-Babef, Marta Iraola and Gerardo Fortuna.

Psilocybin, MDMA or LSD might associate with party drugs but their therapeutic value is being discovered worldwide.

Psilocybin, MDMA or LSD might associate with party drugs but their therapeutic value is being discovered worldwide. Ian Roullier took part in two clinical trials that looked at the effects of psilocybin on depression. Through his personal experience, Roullier shares his insights on psychedelic-assisted therapy, its potential value to patients and what is needed to boost research in this field.

The new EU pharmaceutical strategy should broaden its approach to rare diseases, patients say. While welcoming the proposal, patient associations ask for more measures to assure access to orphan drugs.

New global digital COVID-19 certification system. The World Health Organisation (WHO) and the European Commission have launched the global digital health certification network. The aim is to establish a global system to facilitate global mobility and protect citizens across the world from ongoing and future health threats.

New recommendations on COVID-19 vaccination for next autumn. EU health agencies recommended updating COVID-19 vaccines to target a subgroup of Omicron, with hopes to advance protection from infection and mild-symptomatic disease.

Post-transplant journey should be carefully managed to help patients and caregivers. Despite the widespread belief that organ transplantation is a permanent solution, in most cases it is the start of another lifelong journey.

Shortages of healthcare workers should be urgently addressed. According to health workforce experts, the EU needs to establish monitoring and funding schemes as part of a common European response to take the lead in addressing healthcare labour shortages.

WHO launches the Tuberculosis research tracker. The World Health Organisation (WHO) Global Tuberculosis (TB) Programme will use this tracker to monitor the progress in the development of new treatments, vaccines as well as operational research projects. The online platform will foster the most recent information on TB clinical trials and research studies.

New measures are necessary to ensure equal access to safe fertility treatments across Europe. Fertility Europe and the European Parliamentary Forum for Sexual & Reproductive Rights presented yesterday (6 June) the White Paper The Imperative of Equal Access to Fertility Treatments across Europe. The aim is to present accurate data and information on infertility, its prevalence and implications. It also aims to put the focus on the differences in access across the EU.

WHO and the UK to strengthen their collaboration against global health threats. According to a press release, WHO Director-General Dr Tedros Adhanom Ghebreyesus and UK Secretary of State for Health and Social Care Steve Barclay MP met yesterday (6 June) in London to discuss shared global health priorities. Some of the topics this collaboration will address are the war in Ukraine, the fight against superbugs and the preparedness strategy for possible future pandemics.

PARIS

French warn Irish bottle labelling sets ‘dangerous precedent’. French wine exporters have criticised Ireland's plans to require extensive health labelling on alcoholic beverages that received the European Commission's stamp of approval in January, saying it sets a dangerous precedent and could distort competition on the EU single market. By Clara Bauer-Babef | EURACTIV.fr

French senate confirms alarming increase of drug shortages. Drug shortages have increased at an alarming rate over the past five years in France, from about 800 in 2018 to about 3,000 today, the chairwoman of the Senate Inquiry Committee on Drug Shortages, Sonia de La Provôté, said on Wednesday 31 May. By Clara Bauer-Babef | EURACTIV.fr

Abortion now on the table of Finnish government talks. The Christian Democrats are pushing for the right of healthcare workers to refuse to carry out abortions amid the now five-week-long government talks, Hufvudstadsbladet reported on Thursday. By Pekka Vanttinen | EURACTIV.com

Conditions of EU’ Pfizer talks ‘outrageous’, Polish health minister. Poland will not join the new COVID-19 vaccine deal negotiated by the EU on behalf of the member states, according to Polish Health Minister Adam Niedzielski, who called Pfizer's demand for payments for the undelivered doses outrageous. By Aleksandra Krzysztoszek | EURACTIV.pl

12-14 June| Radical Health Festival Helsinki with TEHDAS stakeholder forum.

13 June | How can we evaluate participatory governance and its impact on health system performance?

20 June | How can we use health system performance assessment to support pandemic preparedness?

[Edited by Nathalie Weatherald]

Print Email Facebook Twitter LinkedIn WhatsApp Telegram